Pages that link to "Q42200895"

The following pages link to Identification of novel virus-specific antigens by CD4⁺ and CD8⁺ T cells from asymptomatic HSV-2 seropositive and seronegative donors (Q42200895):

Displaying 23 items.

• Malaria vaccines: identifying Plasmodium falciparum liver-stage targets (Q26781372) (← links)
• HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgeni (Q35122383) (← links)
• Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV. (Q35506920) (← links)
• Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins (Q35914319) (← links)
• Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response Profile (Q36211625) (← links)
• Large screen approaches to identify novel malaria vaccine candidates (Q36510147) (← links)
• Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses (Q36601101) (← links)
• Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocul (Q37560770) (← links)
• An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1. (Q37561211) (← links)
• Identification of Chlamydia trachomatis Antigens Recognized by T Cells From Highly Exposed Women Who Limit or Resist Genital Tract Infection (Q37835589) (← links)
• Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Rese (Q38947443) (← links)
• A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4+ and CD8+ T Cells (Q40067153) (← links)
• Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial (Q40280300) (← links)
• Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial (Q40536085) (← links)
• Status of vaccine research and development of vaccines for herpes simplex virus (Q40757139) (← links)
• Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017. (Q45323563) (← links)
• Preclinical and clinical development of neoantigen vaccines (Q49668436) (← links)
• Phenotypic and Functional Signatures of Herpes Simplex Virus-Specific Effector Memory CD73CD45RACCR7CD8 T and CD73CD45RACCR7CD8 T Cells Are Associated with Asymptomatic Ocular Herpes (Q57464717) (← links)
• Blockade of LAG-3 Immune Checkpoint Combined With Therapeutic Vaccination Restore the Function of Tissue-Resident Anti-viral CD8 T Cells and Protect Against Recurrent Ocular Herpes Simplex Infection and Disease (Q60951075) (← links)
• Herpes Simplex Virus Evasion of Early Host Antiviral Responses (Q64078553) (← links)
• A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection (Q90520696) (← links)
• Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection agains (Q91760722) (← links)
• Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8+ TRM Cells and Reduces Ocular Herpes Simplex Infection and Disease in HLA Transgenic Rabbits (Q92883499) (← links)